Programmable multifunctional microrobots for synergistic cuproptosis-immunotherapy
Clicks: 3
ID: 324861
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.6
/100
3 views
1 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #243 of 284 articles by views in national science review
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 284 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Oral microrobots as drug carriers have shown great promise in enhancing the therapeutic efficacy of colorectal cancer (CRC). However, existing platforms frequently lack the programmable temporal precision required to execute complex, multi-stage dosing regimens. Here, we report a programmable temporal-responsive microrobot (PTRM) that autonomously navigates across the gastric acid barrier under external magnetic guidance to execute a sequential drug-release program at orthotopic tumor sites. The PTRM is engineered with a logic-gated architecture, featuring a spatially specific shell for gastric-resistant shielding and exclusive intestinal pH-triggered activation. The system’s internal ‘timer’ is governed by the precise modulation of crosslinking densities within its dual gelatin cores, enabling finely-tuned biphasic release kinetics. Phase 1 executes the programmed release of elesclomol to induce tumor cell cuproptosis, successfully priming the tumor microenvironment (TME) by recruiting infiltrating immune cells. Following a precisely tuned 5.5 h interval, Phase 2 triggers the release of PD-1 inhibitors to activate these cells, thereby amplifying immunogenic cell death (ICD). This orchestrated sequential cytotoxicity achieved a 76% remission rate in an orthotopic CRC mouse model. Furthermore, the PTRM architecture is highly scalable, accommodating up to six-core configurations for multi-phase release—establishing a versatile robotic platform for complex combinatorial therapeutic strategies against recalcitrant cancers.
| Reference Key |
openalex_W7202342740
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Chuanhua Li, Jiaxin Li, Xuejia Liu, Xuyang Chen, Shixiao Ding, Yu Zhao, Xiao Luo, Leike Li, Laishou Yang, Shimin Yu, Hao Chang, Fengtong Ji, Tianlong Li, Jie Zhao |
| Journal | national science review |
| Year | 2026 |
| DOI |
10.1093/nsr/nwag491
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.